Carisma Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Carisma Therapeutics

06/11/2024 14:17

* Carisma Therapeutics Inc  CARM.OQ   CARM.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
7 (estimated) for the period ending September 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 42.8% increase in revenue to $5.467 million from $3.83 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Carisma Therapeutics Inc
is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is 8.00​, above​ its last closing price
of $1.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.31       -0.30      -0.27     Beat    9.2
 Mar. 31 2024  -0.47       -0.43      -0.46     Missed  -6.4
 Jan. 1 0001               -0.55      -0.52     Beat    5.9​
 Sep. 30 2023  -0.56       -0.57      -0.53     Beat    7
 ​​Jun.        -0.60       -0.60      -0.49     Beat    17.9
 30 2023                                                
 Jan. 1 0001   -0.89       -0.89      -1.93     Missed  -116.9
                                                        ​
 Dec. 31 2022  -2.20       -2.20      -0.80     Beat    63.6
 Sep. 30 2022  -1.60       -1.60      2.00      Beat    225
 This summary was machine generated November 6 at 14:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)